Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study
In conclusion, BGG492 showed reduction of both tinnitus loudness and annoyance after a single dose and reduction of tinnitus handicap after 2 weeks of treatment in patients with chronic subjective tinnitus, thereby supporting further clinical investigation of AMPA receptor antagonists with an improved benefit/risk ratio. A dose of 100mg TID BGG492 showed higher efficacy but somewhat lower tolerability compared to 50mg TID.PMID:33637230 | DOI:10.1016/bs.pbr.2020.12.004
Source: Brain Research - Category: Neurology Authors: Klaus Kucher Donald Johns Frank Wagner Khalid Abd-Elaziz Caroline Derne Oleksandr Sverdlov Christian U Pfister Berthold Langguth Source Type: research